TrialThe Lancet. Respiratory medicine2021

Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial.

Jordan J Feld et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.